Ser18

Site Information
IsPDEDsssyssNsD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3212919

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	breast cancer ( 2 ) , lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 4 ) , HepG2 (hepatic) ( 3 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , HMLER ('stem, breast cancer') ( 2 ) , PC9 (pulmonary) ( 1 )

References
1	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
2	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
3	Possemato A (2009) CST Curation Set: 7395; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
4	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info